Sublocade Solution
NDC Package 12496-0300-1
Package Information
Sublocade (buprenorphine) solution is sUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. This formulation utilizes a solution delivery system. Marketed by Indivior Inc., this product is identified by NDC 12496-0300 and is authorized under FDA application NDA209819.
Identification & Billing
- RxCUI: 1996184 - buprenorphine 100 MG in 0.5 mL Prefilled Syringe
- RxCUI: 1996184 - 0.5 ML buprenorphine 200 MG/ML Prefilled Syringe
- RxCUI: 1996184 - buprenorphine 100 MG per 0.5 ML Prefilled Syringe
- RxCUI: 1996189 - SUBLOCADE 100 MG in 0.5 mL Prefilled Syringe
- RxCUI: 1996189 - 0.5 ML buprenorphine 200 MG/ML Prefilled Syringe [Sublocade]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 12496 - Indivior Inc.
- 12496-0300 - Sublocade
- 12496-0300-1 - 1 POUCH in 1 CARTON / 1 SYRINGE in 1 POUCH (12496-0300-2) / 1 SOLUTION in 1 SYRINGE (12496-0300-5)
- 12496-0300 - Sublocade
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 12496-0300-1 identifies a specific commercial package of 1 pouch in 1 carton / 1 syringe in 1 pouch (12496-0300-2) / 1 solution in 1 syringe (12496-0300-5) of Sublocade, a human prescription drug labeled by Indivior Inc.. This solution is formulated for subcutaneous use and contains buprenorphine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Indivior Inc. on February 26, 2018. The current certification is valid through December 31, 2027.
How is this Indivior Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 12496030001. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.